Background The infection rate of methicillin-resistant Staphylococcus aureus （MRSA） is increasing yearly due to the overprescription of antibiotics. Traditional Chinese compound medicines are less inclined to induce...Background The infection rate of methicillin-resistant Staphylococcus aureus （MRSA） is increasing yearly due to the overprescription of antibiotics. Traditional Chinese compound medicines are less inclined to induce bacterial resistance in the clinical setting because of their multi-acting mechanisms. However, most current research is limited to bacteriostasis in vitro using single extracts or formulations. Plasma pharmacology is an in vitro method, using what is called ＂medicine serum＂. The aim of this study was to investigate whether the medicine serum of compound Qingre granules （QRKL） alone or in combination with antibiotics may treat MRSA infection in the clinic. Methods An animal model of MRSA resistance was created by injecting rabbits with the standard strain of MRSA ATCC43300. Infected rabbits were treated with QRKL by intragastric administration. Sixty minutes after the last intragastric administration, serum was obtained from the rabbits by heart puncture to obtain what is termed ＂medicine serum＂. The minimum inhibitory concentration （MIC） of QRKL, medicine serum alone, or serum combined with antibiotics was assessed by agar dilution. Results were compared with the growth of sixteen isolates of MRSA. Results The MIC of QRKL to the standard strain ATCC43300 was 10.00 mg/ml. The MICgo of vancomycin was 1.00 pg/ml, which, when combined with QRKL, dropped to 0.50 lJg/ml. The MICg0 of cefuroxime alone was 512.00 pg/ml. This level also decreased to 256.00 tJg/ml when combined with QRKL. The addition of QRKL thus significantly reduced the MIC of both cefuroxime and vancomycin compared with antibiotics alone （P 〈0.01）. The MICgo of vancomycin with medicine serum decreased to 0.50 pg/ml, and the MIC of vancomycin with medicine serum also descended compared with using vancomycin alone （P 〈0.01）. Conclusions The growth of MRSA can be inhibited by QRKL or medicine serum of QRKL in vitro. The addition of QRKL results in increased sensitivity of MRSA to vancomycin and this may provide a novel treatment for patients with MRSA infection.展开更多
Benign recurrent intrahepatic cholestasis （BRIC） is a Prare autosomal recessive liver disease characterizedby intermittent attacks of cholestasis that was first reported by Summerskill and Walshe in 1959.1 A few rep...Benign recurrent intrahepatic cholestasis （BRIC） is a Prare autosomal recessive liver disease characterizedby intermittent attacks of cholestasis that was first reported by Summerskill and Walshe in 1959.1 A few reports on patients with BRIC in China have been described in recent years, however, it is still a challenge to give the patients a correct diagnosis. Therefore, we collected five cases in the Beijing Friendship Hospital and the China-Japan Friendship Hospital in the past two years to summarize their clinical features, and explore the mutation region of the ATP8B1 gene from Chinese patients with BRIC.展开更多
基金The study was supported by the grant from Beijing National Science Foundation of China （No. 51510）.
文摘Background The infection rate of methicillin-resistant Staphylococcus aureus （MRSA） is increasing yearly due to the overprescription of antibiotics. Traditional Chinese compound medicines are less inclined to induce bacterial resistance in the clinical setting because of their multi-acting mechanisms. However, most current research is limited to bacteriostasis in vitro using single extracts or formulations. Plasma pharmacology is an in vitro method, using what is called ＂medicine serum＂. The aim of this study was to investigate whether the medicine serum of compound Qingre granules （QRKL） alone or in combination with antibiotics may treat MRSA infection in the clinic. Methods An animal model of MRSA resistance was created by injecting rabbits with the standard strain of MRSA ATCC43300. Infected rabbits were treated with QRKL by intragastric administration. Sixty minutes after the last intragastric administration, serum was obtained from the rabbits by heart puncture to obtain what is termed ＂medicine serum＂. The minimum inhibitory concentration （MIC） of QRKL, medicine serum alone, or serum combined with antibiotics was assessed by agar dilution. Results were compared with the growth of sixteen isolates of MRSA. Results The MIC of QRKL to the standard strain ATCC43300 was 10.00 mg/ml. The MICgo of vancomycin was 1.00 pg/ml, which, when combined with QRKL, dropped to 0.50 lJg/ml. The MICg0 of cefuroxime alone was 512.00 pg/ml. This level also decreased to 256.00 tJg/ml when combined with QRKL. The addition of QRKL thus significantly reduced the MIC of both cefuroxime and vancomycin compared with antibiotics alone （P 〈0.01）. The MICgo of vancomycin with medicine serum decreased to 0.50 pg/ml, and the MIC of vancomycin with medicine serum also descended compared with using vancomycin alone （P 〈0.01）. Conclusions The growth of MRSA can be inhibited by QRKL or medicine serum of QRKL in vitro. The addition of QRKL results in increased sensitivity of MRSA to vancomycin and this may provide a novel treatment for patients with MRSA infection.
文摘Benign recurrent intrahepatic cholestasis （BRIC） is a Prare autosomal recessive liver disease characterizedby intermittent attacks of cholestasis that was first reported by Summerskill and Walshe in 1959.1 A few reports on patients with BRIC in China have been described in recent years, however, it is still a challenge to give the patients a correct diagnosis. Therefore, we collected five cases in the Beijing Friendship Hospital and the China-Japan Friendship Hospital in the past two years to summarize their clinical features, and explore the mutation region of the ATP8B1 gene from Chinese patients with BRIC.
